Enlivex (Nasdaq: ENLV) - FY25 Financial Results Webcast Replay

Watch our replay of Enlivex’s FY25 Financial Results Webcast to hear management discuss the company’s outlook, financial performance, and its differentiated dual strategy combining quality longevity therapeutics with a prediction markets treasury model.Key FY2025 Highlights:• Net income of $1.23 billion• Diluted EPS of $25.48• Total treasury and treasury-related derivative assets of $2.31 billion• Shareholders’ equity of $1.93 billion• $30.0 million in cash, cash equivalents, and short-term investments in digital assetsEnlivex is positioning itself as a public market vehicle with exposure to two high-interest themes:• Quality longevity therapeutics, led by Allocetra™ and its focus on inflammatory conditions associated with aging• Prediction markets infrastructure, through treasury exposure tied to the RAIN protocol👉 Enlivex is a client of RedChip. Visit https://www.ENLVinfo.com to learn more and sign up for news alerts.#ENLV #Enlivex #Nasdaq #SmallCapStocks #MicroCapStocks #BiotechStocks #GrowthStocks #StockMarket #InvestorUpdate #Earnings #HealthcareStocks #Longevity #DigitalAssets